R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Manager - Field Market Access

Sales & Account ManagementPosted on Nov 10
Full-timeRemote in SpainNo salary listed

About the Job

Requirements

  • A master's or bachelor's degree (MA, MS, BA, or BS).
  • At least 10 years of pharmaceutical-industry experience engaging with Regional Health Administrations and dependent organizations.
  • In-depth knowledge of the national health system and the health policies of the assigned Autonomous Communities.
  • Knowledge of and leadership in relationships with pharmaceutical-industry stakeholders at all levels within assigned health organizations.
  • Deep scientific knowledge and the ability to defend and communicate the value of clinical aspects in the relevant therapeutic areas.
  • Demonstrated success launching drugs in regional and hospital markets.
  • Experience negotiating drug pricing and reimbursement conditions with public administrations and health authorities at regional and hospital levels.
  • Ability to set priorities and work to tight timelines, and willingness to travel mainly within Spain approximately 60% to 70% of the time.

Responsibilities

  • Define and implement market-access strategies to secure access to company products at regional and hospital levels by demonstrating therapeutic, economic, and societal value, using deep knowledge of the regional environment and collaborating with Senior Oncology Account Managers.
  • Manage and maintain institutional relationships with regional health administration professionals in assigned Autonomous Communities, including decision-makers, evaluators, influencers, and advisers, and with hospital management and medical directors who influence pharmaceutical policy and drug evaluation and positioning; serve as the main interlocutor presenting and advising on the product portfolio.
  • Lead regional product introductions and support Senior Oncology Account Managers in hospital pharmacies as needed.
  • Support negotiations at regional services and hospitals, including tenders, negotiated procedures and offers, purchasing centers, and regional framework agreements.
  • Guide the development and customization of pharmacoeconomic data, cost-effectiveness models, and budget-impact models for subnational stakeholders.
  • Build relationships with Regional Health Authorities, Medical Societies, Scientific Institutions, payers, and Patient Advocacy groups.
  • Communicate relevant changes and trends in local health policy and competitor patient-access activities to the cross-functional team.
  • Comply with all laws, regulations, and policies governing company staff conduct.
  • Visibly embody corporate core values while cultivating an energized team culture focused on patient impact.

Desired Qualifications

  • Experience in oncology is preferred.
  • An advanced degree such as an MBA, PharmD, or PhD is preferred.
  • Strong organization, planning, project-management, technical, and analytical skills are preferred.
  • Written, verbal, and interpersonal communication skills, a structured approach to tasks, and professional appearance are preferred.
  • Ability to adapt to ambiguity and changing priorities, maintain a positive attitude toward change, and operate within agreed financial budgets is preferred.
  • Cross-functional teamwork experience is preferred.
  • Relevant experience in areas such as sales operations or marketing is preferred.
  • Ability to work independently to execute strategic and tactical plans under tight timelines is preferred.
  • Ability to deliver compelling presentations to individuals and groups while adapting messaging to engage the audience is preferred.
  • High proficiency with Microsoft PowerPoint, Excel, and Word is preferred.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs